Results 1 to 10 of about 4,895 (140)
Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats. [PDF]
PLoS ONE, 2017 Emerging evidence supports a key role for the gut microbiota in metabolic diseases, including type 2 diabetes (T2D) and obesity. The dipeptidyl peptidase-4 inhibitor vildagliptin is highly efficacious in treating T2D.
Qian Zhang +7 more
doaj +1 more source
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]
Diabetes & Metabolism Journal, 2016 BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim +16 more
doaj +1 more source
Nanofibrous insulin/vildagliptin core-shell PLGA scaffold promotes diabetic wound healing
Frontiers in Bioengineering and Biotechnology, 2023 Introduction: Slow wound repair in diabetes is a serious adverse event that often results in loss of a limb or disability. An advanced and encouraging vehicle is wanted to enhance clinically applicable diabetic wound care.
Chen-Hung Lee +9 more
doaj +1 more source
Clinics and Practice, 2023 (1) Background: There is a high burden of poor glycemic control in the Indian population with type 2 diabetes mellitus (T2DM). Currently, the use of metformin sustained-release (SR)–vildagliptin fixed-dose combination (FDC) is very low as compared to ...
Manoj Chawla +4 more
doaj +1 more source
Molecules, 2021 During forced degradation, the intrinsic stability of active pharmaceutical ingredients (APIs) could be determined and possible impurities that would occur during the shelf life of the drug substance or the drug product could be estimated.
Anna Gumieniczek +4 more
doaj +1 more source
Nanofibrous Vildagliptin/PLGA Membranes Accelerate Diabetic Wound Healing by Angiogenesis
Pharmaceuticals, 2022 The inhibition of dipeptidyl peptidase-4 (DPP4) significantly enhances the wound closure rate in diabetic patients with chronic foot ulcers. DPP4 inhibitors are only prescribed for enteral, but topical administration, if feasible, to a wound would have ...
Chen-Hung Lee +5 more
doaj +1 more source
Archives of Medical Science, 2019 Introduction Dipeptidyl peptidase-4 (DPP-4) inhibitors have various cellular effects that are associated with vascular protection. Here, we examined whether vildagliptin protected endothelial function in diabetic rats and explored the involved mechanism.
Qian Zhang +7 more
doaj +1 more source
Preventive effect of dipeptidyl peptidase-4 inhibitor on atherosclerosis is mainly attributable to incretin's actions in nondiabetic and diabetic apolipoprotein E-null mice. [PDF]
PLoS ONE, 2013 AIM: Several recent reports have revealed that dipeptidyl peptidase (DPP)-4 inhibitors have suppressive effects on atherosclerosis in apolipoprotein E-null (Apoe (-/-)) mice. It remains to be seen, however, whether this effect stems from increased levels
Michishige Terasaki +11 more
doaj +1 more source
The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes [PDF]
Diabetes & Metabolism Journal, 2014 BackgroundWe evaluated the effects of two dipeptidyl peptidase-4 (DPP-4) inhibitors, sitagliptin and vildagliptin, on metabolic parameters in patients with type 2 diabetes mellitus.MethodsA total of 170 type 2 diabetes patients treated with sitagliptin ...
Eun Yeong Choe +10 more
doaj +1 more source
Artificial Cells, Nanomedicine, and Biotechnology, 2019 Elevated free fatty acids (FFAs) are a risk factor for type 2 diabetes. Endothelial dysfunction induced by high levels of FFAs is one of the mechanisms related to the progression of diabetes. In clinical diabetes care, DPP-4 inhibitors have been shown to
Yanyan Qi +3 more
doaj +1 more source